Anti-cd22 antibodies

Abstract

Anti-CD22 antibodies, including isolated nucleic acids that encode at least one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

1 - 28 . (canceled) 
     
     
         29 . A method for producing an anti-CD22 antibody or antibody fragment, comprising:
 expressing said antibody or antibody fragment in a host cell or transgenic animal or transgenic plant or plant cell transformed with a nucleotide sequence encoding said antibody or fragment; and   recovering said antibody or antibody fragment therefrom,   wherein said antibody or antibody fragment binds to human CD22 and comprises heavy and light chain complementarity determining regions (CDRs) derived from the variable regions of one or more of VM1000, VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008, VM1009, VM1010, VM1011, VM1012, VM1013, VM1014, or VM1015, and a constant region derived from one or more human antibodies.   
     
     
         30 . The method according to  claim 29 , wherein said host cell is a mammalian cell, a plant cell or a yeast cell. 
     
     
         31 . The method according to  claim 29 , wherein said transgenic animal is a mammal. 
     
     
         32 . The method according to  claim 31 , wherein said mammal is selected from a goat, a cow, a sheep, a horse, and a non-human primate. 
     
     
         33 . A transgenic animal or plant capable of expressing the antibody or antibody fragment made by the method according to  claim 29 . 
     
     
         34 . An antibody or antibody fragment produced by the method according to  claim 29 . 
     
     
         35 . The method of  claim 29 , wherein said antibody or antibody fragment has a heavy chain variable region having an amino acid sequence of one of SEQ ID NOS: 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, or 64; and a light chain variable region having an amino acid sequence of one of SEQ ID NOS: 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32. 
     
     
         36 . The method of  claim 29 , wherein the expression step comprises introducing an expression vector including the nucleotide sequence encoding the antibody or antibody fragment into the host cell or transgenic animal or transgenic plant or plant cell. 
     
     
         37 . The method of  claim 36 , wherein the expression vector comprises a promoter to direct the expression of the nucleotide sequence encoding the antibody or antibody fragment. 
     
     
         38 . The method of  claim 37 , wherein the promoter is selected from a late SV40 promoter, an early SV40 promoter, a CMV promoter, an HSV tk promoter, a phosphoglycerate kinase promoter, an EF-1 alpha promoter, a human immunoglobulin promoter. 
     
     
         39 . The method of  claim 36 , wherein the expression vector comprises a selectable marker. 
     
     
         40 . The method of  claim 39 , wherein the selectable marker is selected from methotrexate resistance, dihydrofolate reductase resistance, ampicillin resistance, neomycin resistance, mycophenolic acid resistance, glutamine synthetase resistance, tetracycline resistance. 
     
     
         41 . The method of  claim 29 , wherein the host cell is selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, hep G2, P3X63Ag8.653, SP2/0-Ag14, HEK293, HeLa cells. 
     
     
         42 . The method of  claim 29 , wherein the host cell is P3X63Ag8.653 or SP2/0-Ag14. 
     
     
         43 . A composition, comprising the antibody or antibody fragment produced by the method of  claim 29 , and a carrier or diluent. 
     
     
         44 . A method for treating an immune condition, an immune disorder, an immune disease, or a cancerous disorder or cancerous condition in a cell, tissue, organ or animal, comprising:
 contacting the cell, tissue, organ or animal with, or administering to the cell, tissue, organ or animal, an effective amount of the antibody or antibody fragment produced by the method of  claim 29 .   
     
     
         45 . The method according to  claim 44 , wherein said method treats the immune condition, the immune disorder or the immune disease and the immune condition, the immune disorder or the immune disease is at least one selected from rheumatoid arthritis/seronegativearthropathies, osteoarthritis, inflammatory bowel disease, systematic lupus erythematosis, and iridocyclitis/uvetis/optic neuritis. 
     
     
         46 . The method according to  claim 44 , wherein said method treats the cancerous disorder or the cancerous condition and the cancerous disorder or the cancerous condition is at least one selected from leukemia, acute leukemia, acute lymphoblastic leukemia (ALL), B-cell, T-cell or FAB ALL, acute myeloid leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), hairy cell leukemia, myelodyplastic syndrome (MDS), a lymphoma, Hodgkin's disease, a malignant lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, and multiple myeloma. 
     
     
         47 . The method according to  claim 44 , wherein said effective amount is 0.01-100 mg/kilogram of said cells, tissue, organ or animal for treating said immune condition, immune disorder or immune disease, or 0.0001-50 mg/kilogram of said cells, tissue, organ or animal for treating said cancerous disorder or cancerous condition. 
     
     
         48 . The method according to  claim 44 , wherein said contacting or administering is by at least one mode selected from intravenous, intramuscular, bolus, subcutaneous, respiratory, inhalation, vaginal, rectal, buccal, sublingual, intranasal, or transdermal. 
     
     
         49 . A formulation comprising at least one antibody or antibody fragment produced by the method of  claim 29 , and at least one carrier selected from sterile water, sterile buffered water, or at least one preservative selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride, alkylparaben, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof, in an aqueous diluent. 
     
     
         50 . The formulation according to  claim 49 , wherein the concentration of the antibody or antibody fragment in the formulation is from about 0.1 mg/ml to about 100 mg/ml.